Skip to main content

Adagio Therapeutics, Inc. (ADGI)

NASDAQ: ADGI · IEX Real-Time Price · USD
51.29
-0.17 (-0.33%)
After-hours:Sep 17, 2021 7:43 PM EDT
51.46
-4.62 (-8.24%)
At close: Sep 17, 4:00 PM
Market Cap5.58B
Revenue (ttm)n/a
Net Income (ttm)-65.32M
Shares Out108.52M
EPS (ttm)-0.60
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,804,930
Open56.02
Previous Close56.08
Day's Range50.28 - 59.50
52-Week Range20.50 - 59.50
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About ADGI

Adagio Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. Our lead product candidate, ADG20, is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent. We have completed enrollment in our first-in-human Phase 1 clinical trial of ADG20. We are also conducting two separate Phase 2/3 clinical trials: ...

IndustryBiotechnology
IPO DateAug 6, 2021
CEOTillman U. Gerngross
Employees49
Stock ExchangeNASDAQ
Ticker SymbolADGI
Full Company Profile

News

Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial

Adagio Therapeutics Inc (NASDAQ: ADGI) announced that the independent data monitoring committee (IDMC) has recommended expanding the ADG20 EVADE Phase 2/3 trial for COVID-19. The IDMC has supported the ...

1 week ago - Benzinga

3 Biotech Stocks That Soared to New Heights Last Week

Find out what these industry favorites are doing to impress investors.

Other symbols:BCYCCERE
1 week ago - The Motley Fool

Adagio Therapeutics Announces Pricing of Initial Public Offering

WALTHAM, Mass.--(BUSINESS WIRE)--Adagio Therapeutics Announces Pricing of Initial Public Offering

1 month ago - Business Wire

COVID-19 antibody biotech Adagio Therapeutics files for a $100 million IPO

Adagio Therapeutics, a Phase 1 biotech developing antibody therapies COVID-19 and other infectious diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

2 months ago - NASDAQ

Adagio Therapeutics IPO Registration Document (S-1)

Adagio Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC